3 Alsheikh-Ali AA, Abourjaily HM, Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose)[J]. Am J Cardiol, 2002, 89(11): 1308-1310.
[4]
4 Egberts AC, Meyboom RH, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples[J]. Drug Saf, 2002, 25(6): 453-458.
7 Norén GN, Bate A, Orre R, et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events[J]. Stat Med, 2006, 25(21): 3740-3757.
9 Qian Y, Ye X, Du W, et al. A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems[J]. Br J Clin Pharmacol, 2010, 69(1): 67-73.
[10]
10 Choi CA, Chang MJ, Choi HD, et al. Application of a drug-interaction detection method to the Korean National Health Insurance claims database[J]. Regul Toxicol Pharmacol, 2013, 67(2): 294-298.
[11]
11 Almenoff JS, DuMouchel W, KindmanLA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interaction in the post-marketing setting[J]. Pharmacoepidemiol Drug Saf, 2003, 12(6): 517-521.
[12]
12 Van Puijenbroek EP, Egberts AC, Meyboom RH, et al. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole[J]. Br J Clin Pharmacol, 1999, 47(6): 689-693.
[13]
13 Wu XT, Barbar D, Ye Y. Screening and interpreting multi-item associations based on log-linear modeling[C]//ACM SIGKDD International Conference on Knowledge Discovery and Date Mining. Washington, DC: SIGKDD, 2003: 276-285.
[14]
14 Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database[J]. Br J Clin Pharmacol, 2007, 64(4): 489-495.
[15]
15 Norén GB, Bate A, Johansson K, et al. Duplicate detection in the WHO adverse drug reaction database[DB/OL]. [2013-12-. http://www.who-umc.org/graphics/9717.pdf.
17 Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf, 2009, 18(6): 427-436.
[18]
18 Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports[J]. J Am Med Inform Assoc, 2011, 19(1): 79-85.
[19]
19 Tatonetti NP, Denny JC, Murphy SN, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels[J]. Clin Pharmacol Ther, 2011, 90(1): 133-142.
[20]
20 Gooden KM, Pan X, Kawabata H, et al. Use of an algorithm for identifying hidden drug-drug interactions in adverse event reports[J]. J Am Med Inform Assoc, 2013, 20(3): 590.
[21]
21 Tatonetti NP, Denny JC, Altman RB. Response to “Use of an algorithm for identifying hidden drug-drug interactions in adverse event reports” by Gooden et al[J]. J Am Med Inform Assoc, 2013, 20(3): 591.
[22]
22 Cami A, Manzi S, Arnold A, et al. Pharmacointeraction network models predict unknown drug-drug interactions[J]. PLoS One, 2013, 8(4): 1-9.
